Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Wellington Shields & Co. LLC


Share on StockTwits

Wellington Shields & Co. LLC decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 5.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 61,905 shares of the life sciences company’s stock after selling 3,850 shares during the period. Illumina makes up 8.2% of Wellington Shields & Co. LLC’s portfolio, making the stock its 2nd largest position. Wellington Shields & Co. LLC’s holdings in Illumina were worth $22,905,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in ILMN. Bristlecone Advisors LLC boosted its stake in Illumina by 0.7% in the 4th quarter. Bristlecone Advisors LLC now owns 3,816 shares of the life sciences company’s stock worth $1,412,000 after purchasing an additional 27 shares during the period. Blue Fin Capital Inc. boosted its stake in shares of Illumina by 3.1% during the 4th quarter. Blue Fin Capital Inc. now owns 975 shares of the life sciences company’s stock worth $360,000 after buying an additional 29 shares during the last quarter. Sage Capital Advisors llc boosted its stake in shares of Illumina by 0.5% during the 4th quarter. Sage Capital Advisors llc now owns 5,735 shares of the life sciences company’s stock worth $2,458,000 after buying an additional 29 shares during the last quarter. Smithfield Trust Co. boosted its stake in shares of Illumina by 6.0% during the 3rd quarter. Smithfield Trust Co. now owns 584 shares of the life sciences company’s stock worth $180,000 after buying an additional 33 shares during the last quarter. Finally, Scott & Selber Inc. boosted its stake in shares of Illumina by 0.5% during the 3rd quarter. Scott & Selber Inc. now owns 7,014 shares of the life sciences company’s stock worth $2,168,000 after buying an additional 34 shares during the last quarter. 89.97% of the stock is owned by institutional investors.

Shares of ILMN traded down $10.47 during mid-day trading on Tuesday, hitting $460.09. 13,410 shares of the company’s stock were exchanged, compared to its average volume of 1,222,720. Illumina, Inc. has a 52 week low of $196.78 and a 52 week high of $555.77. The stock’s 50-day simple moving average is $423.37 and its 200-day simple moving average is $354.30. The firm has a market cap of $67.13 billion, a price-to-earnings ratio of 109.18, a price-to-earnings-growth ratio of 9.83 and a beta of 1.14. The company has a quick ratio of 3.51, a current ratio of 3.88 and a debt-to-equity ratio of 0.14.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 11th. The life sciences company reported $1.22 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.11. Illumina had a net margin of 19.70% and a return on equity of 15.93%. Analysts forecast that Illumina, Inc. will post 4.39 earnings per share for the current fiscal year.

A number of research firms have recently commented on ILMN. SVB Leerink increased their price objective on shares of Illumina from $360.00 to $470.00 and gave the stock an “outperform” rating in a research note on Friday, February 12th. OTR Global upgraded shares of Illumina to a “positive” rating in a research note on Tuesday, December 22nd. BTIG Research upped their target price on shares of Illumina from $410.00 to $570.00 and gave the company a “buy” rating in a report on Tuesday, February 16th. Argus dropped their target price on shares of Illumina from $380.00 to $355.00 in a report on Tuesday, December 1st. Finally, Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating and set a $351.00 target price on the stock. in a report on Wednesday, December 2nd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $364.60.

In related news, Director Jay T. Flatley sold 4,000 shares of the stock in a transaction that occurred on Tuesday, December 1st. The shares were sold at an average price of $323.90, for a total transaction of $1,295,600.00. Also, SVP Charles Dadswell sold 1,694 shares of the stock in a transaction that occurred on Tuesday, December 1st. The stock was sold at an average price of $323.86, for a total transaction of $548,618.84. Following the sale, the senior vice president now owns 3,460 shares in the company, valued at approximately $1,120,555.60. The disclosure for this sale can be found here. Insiders have sold 32,619 shares of company stock worth $11,528,257 over the last ninety days. Insiders own 0.38% of the company’s stock.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Further Reading: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.